MARKET

TCRR

TCRR

TCR2 Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.35
+0.25
+2.48%
Closed 16:00 06/01 EDT
OPEN
10.03
PREV CLOSE
10.10
HIGH
10.47
LOW
9.62
VOLUME
104.44K
TURNOVER
--
52 WEEK HIGH
21.06
52 WEEK LOW
5.84
MARKET CAP
249.19M
P/E (TTM)
-4.6578
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TCRR stock price target is 24.67 with a high estimate of 35.00 and a low estimate of 16.00.

EPS

TCRR News

More
TCR² Therapeutics Hires Key Business Development and Regulatory Affairs Cell Therapy Experts to Support Strategic Objectives
GlobeNewswire · 5d ago
61 Stocks Moving In Tuesday's Mid-Day Session
Gainers Mmtec, Inc. (NASDAQ: MTC) shares jumped 98.2% to $2.18 in pre-market trading after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 6d ago
TCR² Therapeutics to Present Data on PD-1 Switch TRuC Enhancement at American Association for Cancer Research (AACR) Virtual Meeting 2020
GlobeNewswire · 05/15 13:30
TCR² Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire · 05/14 11:45
TCR2 Therapeutics Q1 EPS $(0.650) Up From $(4.850) YoY
TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(0.650) per share. This is a 86.6 percent increase over losses of $(4.850) per share from the same period last year.
Benzinga · 05/14 10:46
TCR² Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors
GlobeNewswire · 05/04 11:45
TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors
GlobeNewswire · 04/15 11:45
TCR² Therapeutics to Present at the Goldman Sachs Cell Therapy Day
GlobeNewswire · 04/03 11:00

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About TCRR

TCR2 Therapeutics, Inc. is an immunotherapy company, which is developing novel T cell therapies for patients suffering from cancer. The Company’s T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. The Company has demonstrated anti-tumor activity of TRuC-T cells in preclinical models across various tumor targets. The Company has also developed combinations of TRuC variants with elements designed to sustain the immunotherapeutic response and counteract the immunosuppressive tumor microenvironment. Its platform is highlighted with multiple programs of product candidate, which include TC-210, TC-220, TC-410, TC-110 and TC-310.
More

Webull offers kinds of Tcr2 Therapeutics Inc stock information, including NASDAQ:TCRR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRR stock news, and many more online research tools to help you make informed decisions.